单用或联合应用泛昔洛韦和肝炎灵对乙型肝炎血清标志物的影响

中国临床药理学与治疗学 ›› 2004, Vol. 9 ›› Issue (10): 1190-1192.

单用或联合应用泛昔洛韦和肝炎灵对乙型肝炎血清标志物的影响

陈小苹, 陈学福, 崇雨田¹

广东省人民医院感染科, 广州510080, 广东;
¹中山大学附属第三医院传染科, 广州510630, 广东

收稿日期:2004-09-08 修回日期:2004-10-10 出版日期:2004-10-26 发布日期:2020-11-23
通讯作者: 陈小苹, 女, 副主任医师, 主要从事病毒性肝炎和感染性疾病的诊治和临床研究。Tel:020-83827812-42121 E-mail:Xiaopchen2003 @yahoo. com. cn
基金资助:
广东省科技攻关项目(№粤1999245)

Effects of administration of famciclovir and ganyanling injection alone or in combination on serum marker in patients with chronic hepatitis B

CHEN Xiao-Ping, CHEN Xue-Fu, CHONG Yu-Tian¹

Department of Infection, Guangdong Provincial People' s Hospital, Guangzhou 510080, Guangdong, China;
¹Department of Infection, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, Guangdong, China

Received:2004-09-08 Revised:2004-10-10 Online:2004-10-26 Published:2020-11-23

摘要/Abstract

摘要： 目的: 观察单用或联合应用泛昔洛韦和肝炎灵对乙型肝炎血清标志物的影响, 探讨泛昔洛韦及泛昔洛韦和肝炎灵联合应用抗HBV 的疗效。方法: 112 例初治的慢性乙肝患者, 采用分层随机化法分为3 组。泛昔洛韦组:39 例, 泛昔洛韦500 mg, tid; 肝炎灵组:33 例, 肝炎灵4 ml, 肌注, qod; 联合用药组:40 例, 泛昔洛韦+肝炎灵。每组治疗24 周, 随访24 周。治疗前与治疗后1 、3 、6 、12 个月时复查肝功能、乙肝血清标志物和HBV DNA, 并观察药物不良反应。结果: 治疗结束后3 组HBV DNA 阴转率分别为43. 6 %、18. 2 %、72. 5 %, ALT 复常率分别为69. 2 %、48. 5 %、90. 0 %, 联合用药但与肝炎灵组、泛昔洛韦组比较有统计学差异(P<0. 05); HBeAg 阴转率分别为17. 9 %、9. 1 %、25. 0 %;HBeAg/抗-HBe血清转换率分别为10. 3 %、9. 1 %、17. 5 %, 3 组之间比较均无统计学差异。随访24 周3 组HBV DNA 阴转率分别为28. 2 %、15. 2 %、50. 0 %;HBeAg 阴转率分别为12. 8 %、9. 1 %、27. 5 %。治疗中未发现明显的不良反应。结论: 泛昔洛韦抑制HBV DNA 优于肝炎灵, 联合用药能提高HBV DNA 阴转率, 泛昔洛韦对促进HBeAg 阴转、HBeAg/抗-HBe 血清转换的作用不明显, 联合用药也未能提高此作用;但联合用药增加HBeAg 阴转的持续应答率。

关键词: 泛昔洛韦, 肝炎灵, 联合用药, 乙型肝炎病毒DNA, 乙型肝炎病毒e 抗原

Abstract: AIM: To evaluate HBV-marks after administration of famciclovir and ganyanling injection alone or in combination in the patients with chronic hepatitis B.METHODS: 112 patients with CHB were randomly assigned to three groups: 39 patients were alone administration of famciclovir 0. 5 mg, tid, po (famciclovir group), 33 patients were alone administration of ganyanling injection 4 ml, im, qod (ganyanling group), 40 patients were combination administration of famciclovir 0. 5 mg, tid, po and ganyanling injection 4 ml, im, qod (combination group). All the three groups were investigated for 24 weeks and 24 weeks after therapy. The levels of serum ALT, HBV-marks and HBV-DNA were detected before and after the treatment of 1, 3, 6, and 12 month. In addition, the conversion of HBeAg into HBeAb and the curative effect were observed.RESULTS: The normalization rates of serum ALT and HBV-DNA in combination group were higher than those in famciclovir group and ganyanling group (P<0. 05). There was no significant difference of the normalization rate of HBeAg among three groups. Few side effects were found in the course of treatment. CONCULSION: Famciclovir can inhibit the replication of HBVDNA more effectively than ganyanling injection. The combination administration of famciclovir and ganyanling injection is safe and effective in comparison with administration alone in patients with chronic HBV infection.

Key words: famciclovir, ganyanling injection, combination treatment, HBV-DNA, HBeAg

中图分类号:

R978.7

陈小苹, 陈学福, 崇雨田. 单用或联合应用泛昔洛韦和肝炎灵对乙型肝炎血清标志物的影响[J]. 中国临床药理学与治疗学, 2004, 9(10): 1190-1192.

CHEN Xiao-Ping, CHEN Xue-Fu, CHONG Yu-Tian. Effects of administration of famciclovir and ganyanling injection alone or in combination on serum marker in patients with chronic hepatitis B[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(10): 1190-1192.

[1]	李欣宇, 黄鑫. 美洛昔康的临床应用研究现状[J]. 中国临床药理学与治疗学, 2023, 28(2): 189-197.
[2]	刘丹, 刘明, 金良友, 潘娟, 辛昊儒, 刘梦圆, 李鑫, 郑坤, 冯晓灵. 木香烃内酯抗肿瘤活性研究进展[J]. 中国临床药理学与治疗学, 2023, 28(10): 1168-1176.
[3]	黄伊婷, 沈爱宗. 阿法替尼治疗肺癌的临床疗效与安全性[J]. 中国临床药理学与治疗学, 2021, 26(4): 474-480.
[4]	张嘉萱, 邓顺顺, 邱玛丽, 杨双双. 利培酮单药或联合用药治疗后甲状腺激素水平的变化[J]. 中国临床药理学与治疗学, 2020, 25(10): 1145-1150.
[5]	徐丽丽，陈春林，刘桢宇，胡文. 夫西地酸联合头孢类抗生素缩小金黄色葡萄球菌耐药突变选择窗的研究[J]. 中国临床药理学与治疗学, 2016, 21(9): 995-1000.
[6]	叶金华，靳高凤，刘名义，朱宏平，陈亚军，冯慧玲，熊玉卿. P-糖蛋白介导阿托伐他汀与阿昔莫司摄取转运的相互作用及其机制研究[J]. 中国临床药理学与治疗学, 2015, 20(12): 1392-1396.
[7]	孙黎. 5-氟尿嘧啶配伍姜黄素抑制人胃癌SGC-7901细胞增殖的影响[J]. 中国临床药理学与治疗学, 2015, 20(11): 1245-1249.
[8]	贺敏, 裘福荣, 高成璐, 陈琴, 杨淑娟, 孙怡婕, 蒋健. 肝炎灵注射液在健康人体的药代动力学[J]. 中国临床药理学与治疗学, 2010, 15(11): 1261-1266.
[9]	俞珊, 季晖. 沙利度胺联合用药抗肿瘤研究进展[J]. 中国临床药理学与治疗学, 2009, 14(2): 230-236.
[10]	张兆平, 顾晓峰, 孙国华, 张正正. 氨茶碱和多沙普仑减轻布托啡诺术后镇痛期嗜睡的比较[J]. 中国临床药理学与治疗学, 2008, 13(9): 1021-1023.
[11]	胡海棠, 谭志刚, 王晓丹, 郑家润, 崔盘根, 陈正琴, 陈沄. 泛昔洛韦缓释胶囊的人体药代动力学研究及其特征分析[J]. 中国临床药理学与治疗学, 2008, 13(6): 679-683.
[12]	王占庆, 应翔宇, 许景峰. 抗心肌缺血联合用药的实验研究进展[J]. 中国临床药理学与治疗学, 2006, 11(8): 847-850.
[13]	胡海棠, 陈炳为, 陈启光. 影响泛昔洛韦片治疗带状疱疹疗效的因素分析[J]. 中国临床药理学与治疗学, 2005, 10(5): 542-546.
[14]	虞希冲, 陈醒言, 周红宇, 林丹, 朱桐君. N-乙酰半胱氨酸和氯胺酮联用对脑缺血再灌注损伤的影响[J]. 中国临床药理学与治疗学, 2005, 10(4): 428-431.
[15]	周四喜. 抗高血压药物临床应用分析[J]. 中国临床药理学与治疗学, 2005, 10(4): 466-470.